September 2, 2014: After disappointing results of a phase 3 clinical trial, Exelixis, Inc. (EXEL), announced it will reduce its workforce by about 70%, or approximately 160 people.
September 2, 2014: Novo Nordisk will tighten its focus on the treatment of diabetes and obesity, halting its work on inflammatory disorders. Approximately 400 employees will be affected.
September 2, 2014: ThromboGenics announced the effects of implementing its “standalone strategy,” which included “significantly” reducing its headcount. Medical affairs, market access and pre-clinical research activities in Europe were the most affected.
September 2, 2014: In the most recent edition of the NEJM, Novartis revealed that its investigational heart failure drug, LCZ696, was more effective in comparison to ACE-inhibitor enalapril.